Our Business
Segments

Endo International plc

Headquartered in Dublin, Ireland

$4.0 Billion

in revenue in 2016

+23%

from previous year

U.S. Generic Pharmaceuticals

shape-2

Headquartered in Chestnut Ridge, New York

4th largest U.S. generics company based on market share. Develops, licenses, manufactures, markets and distributes safe, innovative and cost-effective pharmaceuticals with a focus on first-to-file or first-to-market opportunities and high-barrier-to-entry products that are difficult to formulate, difficult to manufacture, or that face complex legal and regulatory challenges. The generics R&D pipeline consists of over 200 products including approximately 120 ANDAs pending with the FDA.

$2.6 Billion in revenue in 2016

Segment Milestones

  • Completed generics restructuring and rationalized the generics portfolio and manufacturing network driving greater efficiency
  • Launched approximately 20 new products including 2 key first-to-file products – quetiapine ER and ezetimibe
  • Filed 27 regulatory submissions

Key Product Lines


shape-2

U.S. Branded Pharmaceuticals

Headquartered in Malvern, Pennsylvania

Focused on developing and marketing high-value, quality branded pharmaceutical products for patients in need. Endo Pharmaceuticals’ portfolio includes products for urology, men’s health, orthopedics, endocrinology and hematology.

$1.2 Billion in revenue in 2016

Segment Milestones

  • Increased demand for XIAFLEX® in Peyronie’s Disease and Dupuytren’s Contracture with sales growing 20% in 2016
  • Highly statistically significant Phase 2b data for XIAFLEX® in Cellulite
  • Enhanced focus on our Specialty Branded Pharmaceuticals after returning BELBUCA™ to our partner and exiting promotion of pain medicines

International Pharmaceuticals

shape-3

Our International Pharmaceuticals businesses included: Paladin Labs, headquartered in Montreal, Canada; SOMAR, headquartered in Mexico City, Mexico; and Litha, headquartered in Midrand, South Africa.

$279 Million in revenue in 2016

Segment Milestones

  • Paladin Labs secured Canadian rights to XIAFLEX® and launched the product in the fourth-quarter 2016
  • Paladin Labs launched NUCYNTA® in the fourth-quarter 2016
  • Initiated a sales process for Litha and related Sub-Sahara African business assets. The sale was announced in February 2017 and expected to close in the second-quarter 2017